Grace Therapeutics (GRCE) Interest Coverage Ratio (2019 - 2026)
Grace Therapeutics (GRCE) posted Interest Coverage Ratio of 1.17 for Q1 2026, up 44.26% sequentially from 2.11 in Q4 2025, and up 99.11% YoY from 0.59 in Q1 2025.
Grace Therapeutics (GRCE) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Interest Coverage Ratio for 7 years, with the latest figure at 1.17 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 99.11% year-over-year to 1.17 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.32 (up 99.38% YoY) and the FY2026 annual result came in at 0.21, up 37.75% from the prior year.
- Interest Coverage Ratio improved to 1.17 in Q1 2026 per GRCE's latest filing, from 2.11 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 0.1 in Q1 2022 and troughed at 2092.0 in Q3 2023.
- A 5-year average of 224.0 and a median of 16.43 in 2024 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2022 and 2023: Interest Coverage Ratio soared 99.61% in 2022, then sank 398426.02% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 0.1 in 2022, then tumbled by 122000.69% to 126.79 in 2023, then surged by 96.62% to 4.28 in 2024, then soared by 50.78% to 2.11 in 2025, then jumped by 44.26% to 1.17 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 1.17, 2.11, and 4.22 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -180.88 |
| Mar 31, 2026 | -1.17 |
| Dec 31, 2025 | -2.11 |
| Sep 30, 2025 | -4.22 |
| Jun 30, 2025 | -5.20 |
| Mar 31, 2025 | -132.63 |
| Dec 31, 2024 | -4.28 |
| Sep 30, 2024 | -16.43 |
| Mar 31, 2024 | -58.27 |
| Dec 31, 2023 | -126.79 |
| Sep 30, 2023 | -2,092.00 |
| Jun 30, 2023 | -54.99 |
| Mar 31, 2023 | -413.84 |
| Mar 31, 2022 | -0.10 |
| Mar 31, 2021 | -26.74 |
| Jun 30, 2019 | -266.87 |